Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .
[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
A total of 100 patients with benign prostatic hyperplasia ( BPH ) and overactive bladder ( OAB ) symptoms ( BPH/OAB ) , enrolled between June 2006 to March 2008 , were r and omly divided into 2 groups of morning medication ( M ) and evening medication ( E ) groups , then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks . Data were available for efficacy analysis on 80 patients ( M group ; 43 , E group ; 37 ) . Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group ( p<0.0001 ) , QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group ( p<0.0001 ) , and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group ( p<0.0001 ) and from 8.6±2.9 to 5.8± 3.3 in the E group ( p<0.0001 ) . There was no significant difference in the incidence of adverse effects between the M group ( 6.1 % ) and E group ( 2.2 % ) . These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration
Naftopidil appears to have similar effects in the urological symptom scores and QoL compared to tamsulosin and silodosin .
Naftopidil has similar sexual adverse events compared to tamsulosin but has fewer compared to silodosin
BACKGROUND Benign prostatic hyperplasia ( BPH ) is a common condition in ageing men that may cause lower urinary tract symptoms ( LUTS ) .
Treatment aims are to relieve symptoms and prevent disease-related complications .
Naftopidil is an alpha-blocker ( AB ) that has a high affinity for the A1d receptor that may have advantages in treating LUTS in this setting .
This is an up date of a Cochrane Review first published in 2009 .
Since that time , several large r and omised controlled trials ( RCTs ) have been reported , making this up date relevant .
OBJECTIVES To evaluate the effects of naftopidil for the treatment of LUTS associated with BPH .